高级检索
当前位置: 首页 > 详情页

Alterations of plasma exosomal proteins and motabolies are associated with the progression of castration-resistant prostate cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation &Research Center (CIRC), Shenzhen Hospital, Southern Medical University,Shenzhen, Guangdong Province, China [2]Department of Urology, HainanGeneral Hospital, Hainan Affiliated Hospital of Hainan Medical University,Haikou, Hainan Province, China [3]Department of Urology, Shenzhen People’sHospital (The Second Clinical Medical College, Jinan University, The FirstAffiliated Hospital, Southern University of Science and Technology), Shenzhen,Guangdong Province, China [4]Department of Urology, Shenzhen Hospital,Southern Medical University, Shenzhen, Guangdong Province, China [5]Departmentof Urology, Tianjin Institute of Urology, The Second Hospital of TianjinMedical University, Tianjin 300211, China [6]School of Biomedical Sciences,The Chinese University of Hong Kong, Hong Kong, SAR, China [7]Departmentof Pathology, School of Basic Medical Sciences, Southern Medical University,Guangzhou 510515, China [8]Department of Endocrinology and Metabolism,Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China [9]Department of Urology, The Third Affiliated Hospital of Southern MedicalUniversity, Guangzhou 510500, China [10]Department of Urology, Nanfang Hospital,Southern Medical University, Guangzhou 510515, China [11]Departmentof Medical Genetics and Developmental Biology, School of Medicine, SoutheastUniversity, Nanjing, China [12]Department of Urology, Guangdong Hospitalof Traditional Chinese Medicine, Zhuhai, Guangdong Province 519015, China
出处:
ISSN:

关键词: PCa CRPC Exosomes Proteomics Metabolomics Biomarkers

摘要:
Current diagnosis tools for prostate cancer (PCa) such as serum PSA detection and prostate biopsy cannot distinguish dormant tumors from invasive malignancies, either be used as prognosis marker for castration resistant prostate cancer (CRPC), the lethal stage of PCa patients. Exosomes have been widely investigated as promising biomarkers for various diseases. We aim to characterize the proteomic and metabolomic profile of exosomes and to evaluate their potential value for the diagnosis of PCa, especially CRPC. We also investigate the functions of some specific exosome biomarkers in the progression of CRPC.Integrated proteomics and metabolomics analysis were performed for plasma-derived exosomes collected from tumor-free controls (TFC), PCa and CRPC patients. Expression of specific exosomal proteins were further validated by targeted 4D-parallel reaction monitoring (PRM) mass spectrometry among the three cohorts. Tissue distribution and functional role of exosomal protein LRG1 was studied in clinical PCa tissue samples and cell line models.Three potential exosomal protein markers were identified. The apolipoprotein E level in PCa samples was 1.7-fold higher than that in TFC (receiver operating characteristic value, 0.74). Similarly, the levels of exosome-derived leucine-rich alpha2-glycoprotein 1 (LRG1) and inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) in the CRPC group were 1.7 and 2.04 times, respectively, higher than those in the PCa group (ROC values, 0.84 and 0.85, respectively), indicating that LRG1 and ITIH3 could serve as predictive markers for CRPC. For metabolomic evaluation of exosomes, a series of differentially expressed metabolites were identified, and a combined metabolite panel showed ROC value of 0.94 for distinguishing PCa from TFC and 0.97 for distinguishing CRPC from PCa. Immunohistochemistry of tissue microarray showed that LRG1 protein was significantly upregulated in advanced prostate cancer and functional assay revealed that ectopic expression of LRG1 can significantly enhance the malignant phenotype of prostate cancer cells. More importantly, PCa cell derived LRG1-overexpressed exosomes remarkably promoted angiogenesis.Integration of proteomics and metabolomics data generated proteomic and metabolic signatures of plasma exosomes that may facilitate discrimination of CRPC from PCa and TFC patients, suggesting the potential of exosomal proteins and metabolites as CRPC markers. The study also confirmed the important role of exosomal protein LRG1 in PCa malignant progression.© 2023. The Author(s).

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验
JCR分区:
出版当年[2021]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation &Research Center (CIRC), Shenzhen Hospital, Southern Medical University,Shenzhen, Guangdong Province, China [11]Departmentof Medical Genetics and Developmental Biology, School of Medicine, SoutheastUniversity, Nanjing, China
共同第一作者:
通讯作者:
通讯机构: [9]Department of Urology, The Third Affiliated Hospital of Southern MedicalUniversity, Guangzhou 510500, China [10]Department of Urology, Nanfang Hospital,Southern Medical University, Guangzhou 510515, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号